Overview
Low-grade, intermediate, Risk non-muscle invasive bladder cancer. (LG-IR-NMIBC)
Coding & Documentation Overview
Low-grade intermediate-risk non–muscle-invasive bladder cancer (LG-IR-NMIBC) is increasingly recognized as a heterogeneous disease state characterized by frequent recurrence and a relatively low risk of progression to muscle-invasive disease. Although typically not life-threatening, LG-IR-NMIBC can impose substantial procedural, surveillance, and quality-of-life burdens due to repeated cystoscopies and transurethral resections of bladder tumors (TURBTs). Intermediate-risk disease may include patients with recurrent or multifocal low-grade Ta tumors, tumors larger than 3 cm, recurrence within one year, frequent recurrences, or a history of prior intravesical treatment in the absence of high-grade disease, carcinoma in situ (CIS), or T1 disease.
Most common services
- Surveillance/diagnostic cystoscopy
- Biopsy and/or fulguration of minor lesions
- TURBT/fulguration selected by largest lesion size
- Intravesical instillation visits (administration + drug supply)
Documentation drivers (prevent denials)
- Largest lesion size (cm) and number of tumors
- Tumor location(s) and recurrence history
- Complete resection vs residual disease suspected
- Path details including Ta / low-grade and whether detrusor muscle is present in specimen
- For intravesical therapy: drug name, dose, route (intravesical), dwell/retention time, NDC and wastage (when required)
Coding patterns (high-level)
- CPT®: diagnostic cystoscopy; biopsy/fulguration; TURBT by size; instillation administration
- ICD-10: C67.x (site-specific bladder cancer)
- Encounter Z-codes: Z51.11 chemo, Z51.12 immunotherapy; Z85.51 surveillance/history
Factors that may impact claim adjudication
- Missing largest lesion size and/or tumor count
- Drug claim missing NDC/dose/units alignment (or missing claim note)
- Biopsy reported without support for distinct lesion or separate-location mapping
- Unclear medical necessity (why treatment now / recurrence context)
Top Questions (quick answers)
How do I choose the TURBT/fulguration code when there are multiple tumors?
Select the code based on the largest lesion size treated in the session. Document the largest size, total number, and locations.
When can I bill a biopsy (52204) with a lesion treatment code?
Biopsy may be separately reportable with size-based TURBT codes only when performed on a distinct lesion or separate-location mapping. Verify NCCI edits and payer policy.
What must be documented for intravesical therapy to support reimbursement?
Document drug name, dose, route (intravesical), dwell/retention time, tolerance, and medical necessity. Include NDC/dose/units details when required by the payer.
What ICD-10 codes are commonly used for intravesical chemo or BCG encounters?
Use C67.x site-specific bladder cancer as appropriate plus Z51.11 for chemo encounters and Z51.12 for immunotherapy encounters. Use Z85.51 for surveillance when no active disease.
How do I code intravesical administration vs. the drug supply?
Administration is typically billed with 51720. Drug supply is billed separately using the payer-accepted HCPCS (or miscellaneous code when required), with units tied to the dose actually administered.
Do I use laterality modifiers (LT/RT) for bladder procedures?
No—bladder is a single organ; laterality modifiers are generally not applicable.
What should the operative report say to support TURBT size selection?
Include the largest lesion size (cm), number of tumors, locations, completeness of resection, and whether detrusor muscle is present in the specimen.
When is modifier -22 appropriate?
Consider modifier -22 when work/time/complexity is well beyond typical (e.g., extensive multifocal disease requiring prolonged resection/fulguration). Document objective details supporting additional work.
Example A — Office/ASC minor recurrence (<0.5 cm)
Clinical: 0.4 cm papillary LG Ta lesion on posterior wall; lesion fulgurated.
Code(s): 52224.
Dx: C67.x site-specific.
Example B — TURBT + immediate mitomycin
Clinical: Two recurrent LG Ta tumors, 1.5 cm and 0.8 cm, completely resected; immediate intravesical mitomycin instilled (40 mg).
Code(s): 52234 (largest lesion 1.5 cm), 51720 (instillation), drug HCPCS per payer (e.g., J9280 units tied to dose).
Dx: C67.x; Z51.11.
Example C — Induction BCG visit (no cystoscopy)
Clinical: Weekly intravesical BCG induction without cystoscopy.
Code(s): 51720 + payer-active BCG HCPCS and units.
Dx: Z51.12 ± C67.x (when treating active disease).
Example D — ZUSDURI™ instillation
Clinical: Office instillation 75 mg (56 mL) for Low-grade, intermediate, Risk non-muscle invasive bladder cancer. (LG-IR-NMIBC).
Code(s): 51720 (administration) + drug billed per payer guidance (J9282) with administered amount and separate line with J9282 and -JW modifier with wastage amount.
Dx: Z51.11 ± C67.x.
Op / procedure note essentials
- Largest tumor size, number, and location(s)
- Complete vs incomplete resection; hemostasis; complications (if any)
- Specimen details including whether detrusor muscle is present
- Recurrence context and risk category (intermediate-risk recurrent LG Ta)
Intravesical therapy visit essentials
- Drug name, dose, route (intravesical), volume (if relevant)
- Dwell/retention time and tolerance/side effects
- Medical necessity (active disease vs adjuvant therapy)
Claim note / NDC essentials (when required)
- NDC, drug name, route, dose given
- Wastage documentation (when applicable and permitted)
- Miscellaneous code narrative elements required by payer
Box 19:
Document NDC, drug name, route, dose given, and wastage (when applicable and permitted). Use your payer’s required format.
Example: 75 mg administered from an 80 mg vial with 5 mg wastage documented.
72493010603 ZUSDURI Instillation ME75 ME5JW
Physician Coding
Low-grade, intermediate, Risk non-muscle invasive bladder cancer. (LG-IR-NMIBC)
Physician Coding & Documentation
Use this tab for physician CPT®/HCPCS selection, ICD-10 patterns, and documentation elements that support
medical necessity and reduce denials.
TURBT/fulguration selection rule: When multiple tumors are treated, select the code based on the
largest lesion size treated in that session and document total tumor burden.
Diagnostic/Surveillance
- 52000 – Cystourethroscopy (diagnostic)
Biopsy & Minor Lesions
- 52204 – Cystourethroscopy with biopsy
- 52214 – Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands
- 52224 – Cystourethroscopy with fulguration/treatment of minor lesion(s) <0.5 cm, with or without biopsy
TURBT / Fulguration by Size
- 52234 – Small tumor(s) 0.5–2.0 cm; fulguration and/or resection
- 52235 – Medium tumor(s) 2.0–5.0 cm; fulguration and/or resection
- 52240 – Large tumor(s) >5.0 cm; fulguration and/or resection
Intravesical Therapy Administration
- 51720 – Bladder instillation (administration)
Drug supply: Bill drug supply separately from administration. Use payer-accepted HCPCS and units tied to dose.
(Box 19 / NDC documentation example and scenarios are in the Overview tab.)
Drug (HCPCS) Examples for Intravesical Therapy
- Mitomycin (traditional vials) – J9280 (Injection, mitomycin, 5 mg)
- Gemcitabine – J9201 (Injection, gemcitabine HCl, 200 mg)
- BCG – Verify current MAC/plan policy; use payer-active J-code and units.
-
Mitomycin for Intravesical Solution (ZUSDURI™) – billed using J9282 and follow NDC/units rules.
Global Period (typical)
- Many transurethral bladder procedures are commonly treated as 0-day global/endoscopic/minor; verify per your MAC fee schedule for each code.
Use C67.x site-specific malignant neoplasm codes and add encounter Z-codes as appropriate.
- C67.0 – Malignant neoplasm of trigone of bladder
- C67.1 – Malignant neoplasm of dome of bladder
- C67.2 – Malignant neoplasm of lateral wall of bladder
- C67.3 – Malignant neoplasm of anterior wall of bladder
- C67.4 – Malignant neoplasm of posterior wall of bladder
- C67.5 – Malignant neoplasm of bladder neck
- C67.6 – Malignant neoplasm of ureteric orifice
- C67.7 – Malignant neoplasm of urachus
- C67.8 – Malignant neoplasm of overlapping sites of bladder
- C67.9 – Malignant neoplasm of bladder, unspecified
- Z51.11 – Encounter for antineoplastic chemotherapy (e.g., mitomycin, gemcitabine)
- Z51.12 – Encounter for antineoplastic immunotherapy (e.g., BCG)
- Z85.51 – Personal history of malignant neoplasm of bladder (surveillance when no active disease)
Note: ICD-10-CM does not capture grade/stage—keep these in the clinical documentation.
Ensure these are explicit in the note/op note:
- Pathology & Stage/Grade: e.g., Ta, low-grade (no CIS). Include variant histology, lymphovascular invasion (if present), and whether detrusor muscle is present in specimen.
- Tumor Burden: size (cm) of largest tumor, number (solitary vs. multifocal), and location(s).
- Recurrence History: date of prior TURBT(s), time since last recurrence, and response/tolerance to prior intravesical therapy with start/stop dates.
- Resection Quality: complete resection vs. residual disease suspected; hemostasis achieved.
- Immediate Post-op Instillation (if given): agent, dose, route (intravesical), and dwell/retention time.
- Planned Course: induction/maintenance schedule or re-TURBT plan; surveillance interval.
- Medical Necessity: symptoms (e.g., hematuria), cystoscopy findings, guideline risk category (intermediate-risk, recurrent LG Ta), and why intervention is required now.
Checklist – What to Include in the Op/Procedure Note
- Largest tumor size and number; location(s)
- Complete vs. incomplete resection; detrusor muscle present/absent
- Hemostasis achieved; complications (if any)
- Agent/dose/units/retention for any intravesical therapy
- Risk category and planned surveillance interval
Practice Tips
- Standardize template phrases for size/number/location and agent/dose/dwell time to reduce denials.
- When multifocal, document largest size + aggregate burden; choose the code off the largest lesion.
- Align HCPCS units and payer-required NDC reporting to the actual dose administered.
-
Biopsy bundling: 52204 may be bundled into certain lesion-treatment codes (e.g., 52224).
Biopsy may be separately reportable with size-based TURBT codes (52234–52240) only when performed on a
distinct lesion or separate-location mapping. Verify NCCI edits and payer policy.
-
Single code for multiple tumors: Choose based on the largest lesion treated and document total tumor burden.
-
Modifier –22: Consider when complexity/time is well beyond typical (e.g., extensive multifocal disease). Justify with clear operative detail.
-
Laterality modifiers (LT/RT): Not applicable to bladder (single organ).
-
Claims narrative: For “miscellaneous” drug codes, ensure payer-required narrative/NDC/dose documentation is present (see Overview tab).
Facility Coding
Low-grade, intermediate, Risk non-muscle invasive bladder cancer. (LG-IR-NMIBC)
Facility Coding & Documentation
Use this tab for facility charge capture, ICD-10 sequencing concepts, and documentation elements that support
clean outpatient/ASC/hospital billing. (Facility policies vary—align to your MAC/payer and internal charge description master.)
Facility charge capture commonly includes:
- Procedure/OR services: charge capture aligned to the performed endoscopic service (e.g., biopsy/fulguration/TURBT) or instillation of ZUSDURI for recurrent bladder cancer (intallation plus C code).
- Supplies: catheters/irrigation/sterile supplies per facility policy and packaging rules.
- Adjuvant Intravesical therapy: administration workflow + drug/biologic supply when separately payable per payer rules.
- Drug/biologic billing: use payer-accepted HCPCS and units; maintain NDC and dose documentation where required (see Overview tab for a Box 19/NDC example format).
Common facility diagnosis patterns:
- Active treatment: C67.x site-specific bladder cancer (and add encounter Z-codes when payer rules or your internal policy supports sequencing for infusion/instillation encounters).
- Chemo encounter: Z51.11 (e.g., mitomycin, gemcitabine).
- Immunotherapy encounter: Z51.12 (e.g., BCG).
- Surveillance when no active disease: Z85.51 (history of bladder cancer) as appropriate.
Reminder: ICD-10 does not encode grade; ensure clinical documentation clearly states grade/risk category.
- Procedure performed: clear operative report/procedure note supports the correct facility charge/APC grouping.
- Tumor details: largest size, number, and locations support TURBT/fulguration intensity and defensibility.
- Drug/biologic details: name, dose, route (intravesical), dwell time, NDC (when required), wastage (when permitted and required).
- Medical necessity: recurrence history, guideline risk category, and why the service is required now.
- Packaging/Status indicators: some drugs/supplies may be packaged depending on payer and setting.
- Separate payment vs. bundled: confirm whether intravesical drug supply is separately payable for your payer/site of service.
- Denial prevention: missing NDC/dose/units alignment is a common root cause—use a consistent claim-note process (see Overview tab).
- Payer variance: facility billing requirements often differ between Medicare, Medicare Advantage, and commercial payers—standardize internally but validate externally.
 